This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Oncology Learning Zone | PP-PF-ONC-GB-0423, August 2024

Request An Interactive Pharmacist’s Guide
NUBEQA® (darolutamide)
PP-NUB-GB-2388, May 2025
NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide
PP-NUB-GB-2129, March 2025
Motivational Interviewing Course
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
Module 1: MI Course
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
Module 2: MI Course
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
Module 3: MI Course
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
Module 4: MI Course
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)